Published in Am Heart J on March 27, 2012
Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry. Clin Res Cardiol (2014) 1.04
Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants? J Geriatr Cardiol (2016) 0.81
Chronic heart failure: we are fighting the battle, but are we winning the war? Scientifica (Cairo) (2012) 0.75
A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. Thromb J (2015) 0.75
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke (2007) 2.22
Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol (2009) 2.16
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J (2008) 2.09
Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol (2003) 2.09
Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol (2009) 1.81
Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J (2011) 1.75
Prevalence of stroke and related burden among older people living in Latin America, India and China. J Neurol Neurosurg Psychiatry (2011) 1.18
Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ (2001) 1.13
Admissions with atrial fibrillation in a multiracial population in Kuala Lumpur, Malaysia. Int J Cardiol (2003) 0.93
Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart (1997) 0.85
Present concepts in management of atrial fibrillation: From drug therapy to ablation. World J Cardiol (2009) 0.84
Management of atrial fibrillation: translating clinical trial data into clinical practice. Am J Med (2011) 0.82
What's new in stroke? The top 10 studies of 2009-2011: part II. Pol Arch Med Wewn (2011) 0.82
Disparities in end-stage renal disease care in South America. Clin Nephrol (2010) 0.79
Cardiovascular disease in Latin American women. Nutr Metab Cardiovasc Dis (2010) 0.79
The assessment of stroke and bleeding risk in atrial fibrillation: where are we now? Expert Rev Cardiovasc Ther (2010) 0.78
[Recommendations for stroke treatment and prevention, 2004]. Rev Neurol (2004) 0.78
Recent advances in oral anticoagulation for atrial fibrillation. Ther Adv Cardiovasc Dis (2010) 0.78
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA (2010) 6.91
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (2007) 6.88
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Non-evidence-based ICD implantations in the United States. JAMA (2011) 5.05
Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA (2013) 5.05
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA (2007) 4.89
Epidemiology and risk profile of heart failure. Nat Rev Cardiol (2010) 4.88
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med (2010) 4.42
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA (2006) 4.30
Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol (2005) 4.26
Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation (2008) 4.00
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J (2009) 3.57
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44
Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation (2009) 3.43
Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol (2008) 3.35
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation (2011) 3.30
Body mass index and mortality in heart failure: a meta-analysis. Am Heart J (2008) 3.25
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol (2012) 3.24
Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med (2012) 3.08
Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol (2004) 3.08
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA (2012) 3.07
Use of aldosterone antagonists in heart failure. JAMA (2009) 3.00
Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol (2002) 2.97
Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med (2009) 2.97
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J (2012) 2.94
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol (2013) 2.94
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol (2013) 2.89
Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation (2011) 2.88
Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol (2010) 2.86
Sustained firing in auditory cortex evoked by preferred stimuli. Nature (2005) 2.83
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J (2007) 2.80
High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail (2007) 2.75
Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA (2007) 2.75
International variation in and factors associated with hospital readmission after myocardial infarction. JAMA (2012) 2.75
The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res (2004) 2.72
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation (2011) 2.71
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol (2005) 2.71
Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med (2008) 2.65
Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med (2012) 2.64
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes (2012) 2.61
Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm (2012) 2.60
Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol (2006) 2.59
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2006) 2.57
Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. Circ Arrhythm Electrophysiol (2008) 2.55
Racial and ethnic differences in the treatment of acute myocardial infarction: findings from the Get With the Guidelines-Coronary Artery Disease program. Circulation (2010) 2.53
An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol (2013) 2.47
Cardiac troponin and outcome in acute heart failure. N Engl J Med (2008) 2.41
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol (2008) 2.39
Comparison of 30-day mortality models for profiling hospital performance in acute ischemic stroke with vs without adjustment for stroke severity. JAMA (2012) 2.38
Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation (2010) 2.32
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. Arch Intern Med (2010) 2.28
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J (2013) 2.27
Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ (2012) 2.23
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm (2013) 2.22
Renal denervation in moderate to severe CKD. J Am Soc Nephrol (2012) 2.21
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20
Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med (2007) 2.20